中国蒽环类药物在白血病治疗中的临床应用专家共识

2018-03-20 中国抗癌协会肿瘤临床化疗专业委员会 中国肿瘤临床.2018,45(3):117-119.

蒽环类药物是一类对白血病具有高效作用的抗癌药物,主要有柔红霉素(daunorubicn,DNR)、去甲氧柔红霉素(idarubicin,IDA)、米托蒽醌(mitoxantrone,MIT)等。

中文标题:

中国蒽环类药物在白血病治疗中的临床应用专家共识

发布日期:

2018-03-20

简要介绍:

蒽环类药物是一类对白血病具有高效作用的抗癌药物,主要有柔红霉素(daunorubicn,DNR)、去甲氧柔红霉素(idarubicin,IDA)、米托蒽醌(mitoxantrone,MIT)等。

 

拓展指南:白血病相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=中国蒽环类药物在白血病治疗中的临床应用专家共识)] GetToolGuiderByIdResponse(projectId=1, id=26a2d1c0015e5365, title=中国蒽环类药物在白血病治疗中的临床应用专家共识, enTitle=, guiderFrom=中国肿瘤临床.2018,45(3):117-119., authorId=null, author=, summary=蒽环类药物是一类对白血病具有高效作用的抗癌药物,主要有柔红霉素(daunorubicn,DNR)、去甲氧柔红霉素(idarubicin,IDA)、米托蒽醌(mitoxantrone,MIT)等。 , cover=, journalId=null, articlesId=null, associationId=897, associationName=中国抗癌协会肿瘤临床化疗专业委员会, associationIntro=null, copyright=0, guiderPublishedTime=Tue Mar 20 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<P>蒽环类药物是一类对白血病具有高效作用的抗癌药物,主要有柔红霉素(daunorubicn,DNR)、去甲氧柔红霉素(idarubicin,IDA)、米托蒽醌(mitoxantrone,MIT)等。 </P> <P> </P>拓展指南:<strong>与<font color=red>白血病</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=c46081c0015ea969" title="NCCN临床实践指南:慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(2018.V5)" target=_blank>NCCN临床实践指南:慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(2018.V5)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=586e11c0015e180c" title="NCCN临床实践指南:慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(2018.V4)" target=_blank>NCCN临床实践指南:慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(2018.V4)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=232d41c0015631d5" title="NCCN临床实践指南:急性髓性白血病(2018.V1)" target=_blank>NCCN临床实践指南:急性髓性白血病(2018.V1)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=7a9691c00155e5a0" title="NCCN临床实践指南:慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(2018.V3)" target=_blank>NCCN临床实践指南:慢性淋巴细胞白血病/小淋巴细胞淋巴瘤(2018.V3)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=e7ccb1c0015a90bc" title="NCCN临床实践指南:慢性髓性白血病(2018.V4)" target=_blank>NCCN临床实践指南:慢性髓性白血病(2018.V4)</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E7%99%BD%E8%A1%80%E7%97%85" target=_blank>有关白血病更多指南</a></ul>, tagList=[TagDto(tagId=27019, tagName=蒽环类药物), TagDto(tagId=809, tagName=白血病), TagDto(tagId=611, tagName=临床应用)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=8041, appHits=187, showAppHits=9, pcHits=5712, showPcHits=4383, likes=124, shares=7, comments=3, approvalStatus=1, publishedTime=Tue Apr 03 21:59:57 CST 2018, publishedTimeString=2018-03-20, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Tue Apr 03 21:59:57 CST 2018, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 16:34:00 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=中国蒽环类药物在白血病治疗中的临床应用专家共识)])
中国蒽环类药物在白血病治疗中的临床应用专家共识
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=302633, encodeId=196830263333, content=哈哈哈哈宝贝, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/07/8c1e5a0085f3b74f3a4ab58a38a3d487.jpg, createdBy=b33e2159612, createdName=2227437833_79976374, createdTime=Wed Apr 04 08:53:14 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302475, encodeId=50e53024e5a0, content=不错的文章值得拥有, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Tue Apr 03 23:15:22 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302460, encodeId=f9d8302460cb, content=^_^^_^^_^, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Swp2ehfHpiciczeTntUyQOlIGMzQ705ic67sdMTVMbwTv7KbmlUvxrGvRSvQZjPkz7ib5tEDfIaORgczPtmHDpwojg/0, createdBy=c54b2163125, createdName=wqkm, createdTime=Tue Apr 03 22:21:45 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
    2018-04-04 2227437833_79976374

    哈哈哈哈宝贝

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=302633, encodeId=196830263333, content=哈哈哈哈宝贝, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/07/8c1e5a0085f3b74f3a4ab58a38a3d487.jpg, createdBy=b33e2159612, createdName=2227437833_79976374, createdTime=Wed Apr 04 08:53:14 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302475, encodeId=50e53024e5a0, content=不错的文章值得拥有, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Tue Apr 03 23:15:22 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302460, encodeId=f9d8302460cb, content=^_^^_^^_^, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Swp2ehfHpiciczeTntUyQOlIGMzQ705ic67sdMTVMbwTv7KbmlUvxrGvRSvQZjPkz7ib5tEDfIaORgczPtmHDpwojg/0, createdBy=c54b2163125, createdName=wqkm, createdTime=Tue Apr 03 22:21:45 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
    2018-04-03 1e1b8538m79(暂无匿称)

    不错的文章值得拥有

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=302633, encodeId=196830263333, content=哈哈哈哈宝贝, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/07/8c1e5a0085f3b74f3a4ab58a38a3d487.jpg, createdBy=b33e2159612, createdName=2227437833_79976374, createdTime=Wed Apr 04 08:53:14 CST 2018, time=2018-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302475, encodeId=50e53024e5a0, content=不错的文章值得拥有, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eff51996281, createdName=1e1b8538m79(暂无匿称), createdTime=Tue Apr 03 23:15:22 CST 2018, time=2018-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=302460, encodeId=f9d8302460cb, content=^_^^_^^_^, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Swp2ehfHpiciczeTntUyQOlIGMzQ705ic67sdMTVMbwTv7KbmlUvxrGvRSvQZjPkz7ib5tEDfIaORgczPtmHDpwojg/0, createdBy=c54b2163125, createdName=wqkm, createdTime=Tue Apr 03 22:21:45 CST 2018, time=2018-04-03, status=1, ipAttribution=)]
    2018-04-03 wqkm

    ^_^^_^^_^

    0